Vertex announces u.s. fda approval for kalydeco® (ivacaftor) to treat eligible infants with cf ages 1 month and older

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced the u.s. food and drug administration (fda) approved kalydeco® (ivacaftor) for use in children with cystic fibrosis (cf) ages 1 month to less than four months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to kalydeco® based on clinical and/or in vitro assay data. kalydeco® is already approved in the u.s. and eu for the treat.
VRTX Ratings Summary
VRTX Quant Ranking